Coverage for Casgevy (J3392) and Lyfgenia (J3394) for the Sickle Cell Gene Therapy Model

Immediately: Billing team must update billing system to recognize and process HCPCS codes J3392 (Casgevy) and J3394 (Lyfgenia) for Arkansas Medicaid claims. Review the full policy document at https://humanservices.arkansas.gov/wp-content/uploads/ON-007-26.docx to identify any prior authorization requirements, medical necessity documentation needs, or coverage limitations. Update claims submission protocols and provider education materials to reflect new billing codes and any coverage restrictions. Failure to bill correctly may result in claim denials or delays for sickle cell gene therapy patients.